Preclinical Evaluation of Amphihevir, a First-in-Class Clinical Hepatitis C Virus NS4B Inhibitor | Zendy

Xin Tao | Zendy; Ningyu Wang | Zendy; Jianfei Wang | Zendy; Zhifei Fu | Zendy; Zhengxian Gu | Zendy; Yang Zhang | Zendy; Shuhui Chen | Zendy; Lichun Wang | Zendy; Luoting Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preclinical Evaluation of Amphihevir, a First-in-Class Clinical Hepatitis C Virus NS4B Inhibitor

Author(s) -

Xin Tao,

Ningyu Wang,

Jianfei Wang,

Zhifei Fu,

Zhengxian Gu,

Yang Zhang,

Shuhui Chen,

Lichun Wang,

Luoting Yu

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01237-19

Subject(s) - ns5b , replicon , ns3 , hepatitis c virus , pharmacology , virology , hepatitis c , potency , ns5a , biology , pharmacokinetics , genotype , virus , hepacivirus , in vitro , gene , genetics , plasmid

Amphihevir, a benzofuran derivative, is the first reported hepatitis C virus (HCV) nonstructural protein 4B (NS4B) inhibitor that has advanced to clinical trials (currently in phase Ib trial [CTR20170632]). Here, we report the results of a preclinical study of its potency, toxicity, selectivity, drug metabolism and pharmacokinetics (DMPK), and safety profiles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research